Amgen, Inc. vs Iron Mountain Inc — how do they compare? Amgen, Inc. trades at $412.21 (market cap $224.14B), while Iron Mountain Inc trades at $122.41 (market cap $36.44B). The key difference: Amgen, Inc. is far larger — about 6.2× Iron Mountain Inc's market cap, and Iron Mountain Inc pays the higher dividend (2.82%). Which is the better fit depends on your goals.
| AMGN | IRM | |
|---|---|---|
Market Cap | $224.14B | $36.44B |
Sector | Health | Real Estate |
52-Week High | $417.20 | $133.06 |
52-Week Low | $271.18 | $78.86 |
Enterprise Value | $267.45B | $55.85B |
Dividend Yield | 2.43% | 2.82% |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →